![conference banner](/images/conference-banner.jpeg)
Abstract
Angiotensin converting enzyme (ACE) is a key enzyme in the renin angiotensin system (RAS) and converts angiotensin (Ang) I to the vasoconstrictor Ang II, which is thought to be responsible for most of the physiological and pathophysiological effects of the RAS. This classical view of the RAS was challenged with the discovery of the enzyme, ACE2 which both degrades Ang II and leads to formation of the vasodilatory and anti-proliferative peptide, Ang 1-7. Activation of the RAS is a major contributor to diabetic complications, and blockade of the vasoconstrictor and hypertrophic actions of Ang II, slows but does not prevent the progression of such complications. The identification of ACE2 in the heart and kidney adds further complexity to the RAS, provides the rationale to explore the role of this enzyme in pathophysiological states, including the microvascular and macrovascular complications of diabetes. It is believed that ACE2 acts in a counter-regulatory manner to ACE to modulate the balance between vasoconstrictors and vasodilators within the heart and kidney, and may thus play a significant role in the pathophysiology of cardiac and renal disease. Relatively little is known about ACE2 in diabetes, and this review will explore and discuss the data that is currently available. The discovery of ACE2 presents a novel opportunity to develop drugs that specifically influence ACE2 activity and/or expression, and it is possible that such compounds may have considerable clinical value in the prevention and treatment of the complications of diabetes.
Keywords: Diabetes mellitus, ACE2, renin angiotensin system, nephropathy, myocardial infarction, atherosclerosis, retinopathy
Current Pharmaceutical Design
Title: ACE2 and Diabetic Complications
Volume: 13 Issue: 26
Author(s): Rachael G. Dean and Louise M. Burrell
Affiliation:
Keywords: Diabetes mellitus, ACE2, renin angiotensin system, nephropathy, myocardial infarction, atherosclerosis, retinopathy
Abstract: Angiotensin converting enzyme (ACE) is a key enzyme in the renin angiotensin system (RAS) and converts angiotensin (Ang) I to the vasoconstrictor Ang II, which is thought to be responsible for most of the physiological and pathophysiological effects of the RAS. This classical view of the RAS was challenged with the discovery of the enzyme, ACE2 which both degrades Ang II and leads to formation of the vasodilatory and anti-proliferative peptide, Ang 1-7. Activation of the RAS is a major contributor to diabetic complications, and blockade of the vasoconstrictor and hypertrophic actions of Ang II, slows but does not prevent the progression of such complications. The identification of ACE2 in the heart and kidney adds further complexity to the RAS, provides the rationale to explore the role of this enzyme in pathophysiological states, including the microvascular and macrovascular complications of diabetes. It is believed that ACE2 acts in a counter-regulatory manner to ACE to modulate the balance between vasoconstrictors and vasodilators within the heart and kidney, and may thus play a significant role in the pathophysiology of cardiac and renal disease. Relatively little is known about ACE2 in diabetes, and this review will explore and discuss the data that is currently available. The discovery of ACE2 presents a novel opportunity to develop drugs that specifically influence ACE2 activity and/or expression, and it is possible that such compounds may have considerable clinical value in the prevention and treatment of the complications of diabetes.
Export Options
About this article
Cite this article as:
Dean G. Rachael and Burrell M. Louise, ACE2 and Diabetic Complications, Current Pharmaceutical Design 2007; 13 (26) . https://dx.doi.org/10.2174/138161207781662876
DOI https://dx.doi.org/10.2174/138161207781662876 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atherosclerosis and Inflammation: Insight from Carotid and Intracoronary Ultrasound Studies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting RANK/RANKL in the Treatment of Solid Tumours and Myeloma
Current Pharmaceutical Design Role and Therapeutic Potential of Astrocytes in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Routine use of Corticosteroids to Prevent Inflammation Response in Cardiac Surgery
Recent Patents on Cardiovascular Drug Discovery Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry Stage B: What is the Evidence for Treatment of Asymptomatic Left Ventricular Dysfunction?
Current Cardiology Reviews Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Overview of Natural Supplements for the Management of Diabetes and Obesity
Current Diabetes Reviews Genetic Polymorphisms in the Growth Hormone Receptor: Impact on Growth Response and Disease Susceptibility
Current Pharmacogenomics and Personalized Medicine Meet Our Editorial Board Member
Current Vascular Pharmacology Retinal Neurodegeneration in the Course of Diabetes-Pathogenesis and Clinical Perspective
Current Neuropharmacology The Effects of Medications Used for the Management of Dyslipidemia on Postprandial Lipemia
Current Medicinal Chemistry Targeting CNS Transporters for Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Cell Cycle Re-Entry in Alzheimers Disease: A Major Neuropathological Characteristic?
Current Alzheimer Research Pharmacological Management of Diabetic Nephropathy
Current Vascular Pharmacology New Sides of Aldosterone Action in Cardiovascular System as Potential Targets for Therapeutic Intervention
Current Drug Targets DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science Relationship between Compound α-Ketoacid and Microinflammation in Patients with Chronic Kidney Disease
Current Pharmaceutical Design Hypertension and Compliance to Treatment in the Primary Care Setting: Key Issues from the Literature Review
Current Hypertension Reviews Subject Index To Volume 13
Current Medicinal Chemistry